Free Trial Information
BioCentury | Apr 23, 2018
Clinical News

Prothena plummets after amyloidosis failure

...March 31 (see BioCentury, Feb. 9) . Jaime De Leon NEOD001 PRX002, RG7935, RO7046015 PRX004 Celgene Corp. Prothena Corp. plc Roche Alpha synuclein (SNCA) Amyloid Leukocyte cell-derived chemotaxin 2 (LECT2) Microtubule-associated...
Read More
BioCentury | Jan 17, 2013
Distillery Therapeutics

Indication: Infectious disease

...LECT2 could help treat sepsis. In a mouse model of bacterial-induced sepsis, plasma levels of Lect2...
...Lect2 increased survival compared with saline when administered before or during sepsis. In mouse macrophages, Lect2...
...6(2); doi:10.1038/scibx.2013.37 Published online Jan. 17, 2013 Patent application filed in China for use of LECT2...
Read More
BioCentury | Nov 16, 2009
Company News

Endo Pharmaceuticals Inc., LecTec Corp. deal

Endo will receive an exclusive license to two of LecTec's patents covering patches for pain medication in exchange for $23 million. The deal settles patent litigation between the companies in which LecTec filed suit against...
Read More
BioCentury | Jul 14, 1997
Clinical News

LecTec Corp. regulatory update

LECT received U.S. Patent No. 5,643,928 covering the use of cotinine, a non-addictive metabolite of nicotine, for long-term control of body weight in non-nicotine-addicted people. LecTec Corp. (LECT), Minnetonka, Minn. Business: Metabolic WIR Staff...
Read More
BioCentury | Oct 30, 1995
Clinical News

Cotinine fumarate data

LECT presented Phase II data, using 100 mg of the drug, at the meeting of the American Society of Addiction Medicine conference on nicotine dependence in Toronto. The data showed an increase in the rate...
Read More
BioCentury | Apr 24, 1995
Clinical News

Cotinine: Completed a Phase II trial, with a significant number of users of the agent abstaining from smoking during the study, compared to placebo-treated smok

LecTec Corp. (LECT), Minnetonka, Minn. Product: Cotinine, a metabolite of nicotine, in pill form Use: Smoking cessation Status: Completed a Phase II trial, with a significant number of users of the agent abstaining from smoking...
Read More
BioCentury | Jan 3, 1995
Clinical News

InnoVet Inc. regulatory update

IVT will record a loss of $835,000 on the sale, but will be able to pledge its Enviromed shares as collateral and receive 65 percent of their market value as a loan. The financing will...
Read More
BioCentury | Sep 26, 1994
Clinical News

Non-nicotine smoking cessation product: Began Phase II trial

LecTec (LECT), Minnetonka, Minn. Product: Non-nicotine smoking cessation product Indication: Smoking cessation Status: Began Phase II trial of outpatients for a 90-day period; separately, the NIH is conducting a study to determine whether the active...
Read More
BioCentury | Jun 7, 1993
Company News

LecTec Corp. deal

LecTec Corp. (LECT) LecTec Corp. (LECT) entered into an agreement with McNeil Consumer Products to develop a non-nicotine active ingredient for alleviating symptoms of tobacco withdrawal. LecTec said the compound, which is in preclinical trials...
Read More
Items per page:
1 - 9 of 9